Evolus Reports Double-Digit Revenue Growth and Reaffirms 2025 Guidance

Reuters11-06

Evolus Reports Double-Digit Revenue Growth and Reaffirms 2025 Guidance

Evolus Inc. reported its financial results for the third quarter ended September 30, 2025, highlighting double-digit growth despite current market conditions. The company posted total net revenue of $69.0 million, with $63.2 million attributed to global Jeuveau® sales, reflecting sequential growth that exceeded typical seasonal trends. In the U.S., Evolus achieved a year-to-date market share of 14%. The company also generated $5.7 million in revenue from Evolysse™, noting this as the most successful hyaluronic acid (HA) filler launch in over a decade. Strategic expense reductions implemented mid-year lowered operating costs and strengthened the financial position in the second half of the year. Evolus reaffirmed its 2025 net revenue guidance of $295 million to $305 million and projected non-GAAP operating expenses of $208 million to $213 million. The company expects to achieve profitability in the fourth quarter and sustainable annual profitability beginning in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evolus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251105475228) on November 05, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581701439?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 05:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581701439","market":"nz","top_or_hot":-1,"title":"Evolus Reports Double-Digit Revenue Growth and Reaffirms 2025 Guidance","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Evolus Reports Double-Digit Revenue Growth and Reaffirms 2025 Guidance\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/EOLS\">Evolus Inc.</a> reported its financial results for the third quarter ended September 30, 2025, highlighting double-digit growth despite current market conditions. The company posted total net revenue of $69.0 million, with $63.2 million attributed to global Jeuveau® sales, reflecting sequential growth that exceeded typical seasonal trends. In the U.S., Evolus achieved a year-to-date market share of 14%. The company also generated $5.7 million in revenue from Evolysse™, noting this as the most successful hyaluronic acid (HA) filler launch in over a decade. Strategic expense reductions implemented mid-year lowered operating costs and strengthened the financial position in the second half of the year. Evolus reaffirmed its 2025 net revenue guidance of $295 million to $305 million and projected non-GAAP operating expenses of $208 million to $213 million. The company expects to achieve profitability in the fourth quarter and sustainable annual profitability beginning in 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evolus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251105475228) on November 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Evolus Reports Double-Digit Revenue Growth and Reaffirms 2025 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEvolus Reports Double-Digit Revenue Growth and Reaffirms 2025 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-06 05:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Evolus Reports Double-Digit Revenue Growth and Reaffirms 2025 Guidance\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/EOLS\">Evolus Inc.</a> reported its financial results for the third quarter ended September 30, 2025, highlighting double-digit growth despite current market conditions. The company posted total net revenue of $69.0 million, with $63.2 million attributed to global Jeuveau® sales, reflecting sequential growth that exceeded typical seasonal trends. In the U.S., Evolus achieved a year-to-date market share of 14%. The company also generated $5.7 million in revenue from Evolysse™, noting this as the most successful hyaluronic acid (HA) filler launch in over a decade. Strategic expense reductions implemented mid-year lowered operating costs and strengthened the financial position in the second half of the year. Evolus reaffirmed its 2025 net revenue guidance of $295 million to $305 million and projected non-GAAP operating expenses of $208 million to $213 million. The company expects to achieve profitability in the fourth quarter and sustainable annual profitability beginning in 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evolus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251105475228) on November 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EOLS","symbol_name":"Evolus Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL8D4XW:1","article_id":"2581701439","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581701439","pubTimestamp":1762376944,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Evolus Inc. reported its financial results for the third quarter ended September 30, 2025, highlighting double-digit growth despite current market conditions. The company posted total net revenue of $69.0 million, with $63.2 million attributed to global Jeuveau sales, reflecting sequential growth that exceeded typical seasonal trends. In the U.S., Evolus achieved a year-to-date market share of 14%. The company also generated $5.7 million in revenue from Evolysse, noting this as the most successful hyaluronic acid  filler launch in over a decade. Strategic expense reductions implemented mid-year lowered operating costs and strengthened the financial position in the second half of the year. Evolus reaffirmed its 2025 net revenue guidance of $295 million to $305 million and projected non-GAAP operating expenses of $208 million to $213 million. The company expects to achieve profitability in the fourth quarter and sustainable annual profitability beginning in 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EOLS":"Evolus Inc.","BK4007":"制药"},"translate_title":"Evolus报告收入实现两位数增长并重申2025年指引","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EOLS":0.9},"content_text":"Evolus Reports Double-Digit Revenue Growth and Reaffirms 2025 Guidance\n    \n\nEvolus Inc. reported its financial results for the third quarter ended September 30, 2025, highlighting double-digit growth despite current market conditions. The company posted total net revenue of $69.0 million, with $63.2 million attributed to global Jeuveau® sales, reflecting sequential growth that exceeded typical seasonal trends. In the U.S., Evolus achieved a year-to-date market share of 14%. The company also generated $5.7 million in revenue from Evolysse™, noting this as the most successful hyaluronic acid (HA) filler launch in over a decade. Strategic expense reductions implemented mid-year lowered operating costs and strengthened the financial position in the second half of the year. Evolus reaffirmed its 2025 net revenue guidance of $295 million to $305 million and projected non-GAAP operating expenses of $208 million to $213 million. The company expects to achieve profitability in the fourth quarter and sustainable annual profitability beginning in 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evolus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251105475228) on November 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581701439","isCrawlerRequest":true}